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Summary.-The responses of 6 human colorectal tumour xenografts to 7 cytotoxic
agents have been established. Tumour responses have been quantified by growth
inhibition, and the time taken for 3H-thymidine fractional incorporation (TFI) to
recover to the control value after treatment. The chemosensitivity of each tumour
line to a spectrum of agents was individual, and no pattern of response which would
allow prediction of individual agent efficacy was apparent. Cyclophosphamide,
methyl-CCNU and 5-fluorouracil produced marked growth inhibition in individual
tumour lines, whereas actinomycin-D, cis-dichlorodiammine platinum, doxorubicin
and pentamethylmelamine showed little activity. Data presented agree with clinical
evaluation for single-agent therapy. The uptake and incorporation of radiolabelled
5-fluorouracil into 4 tumour lines is reported. No marked differences between 3 FU-
insensitive lines and 1 sensitive line have been observed.
THERE have been several reports of the
sensitivity of human tumour xenografts
maintained in immune-deprived (Kopper
and Steel, 1975; Houghton, Houghton and
Taylor, 1977) or congenitally athymic
mice (Povlsen andJacobsen, 1975; Rofstad
et al., 1977) to chemotherapeutic agents.
The major advantage in using xenografts
rather than conventional rodent tumours
is that they offer a better model of the
human disease, and may act as a more
realistic screen for the selection of new
agents for the treatment of particular
cancer types. The problem associated with
large-bowel cancer is that no clear pattern
of response to current agents has been
established in the human population. It is
therefore questionable whether one or two
xenografts established from patients with
adenocarcinoma of the large bowel would
be representative of the "human disease".
In the current study we present data on
the chemosensitivity of 6 colorectal xeno-
grafts maintained in immune-deprived
mice, which, although not intended to
simulate a human colorectal tumour
population, has allowed the examination
of the response of each tumour line to a
spectrum of chemotherapeutic agents cur-
rently used against large-bowel cancer in
the clinic. 5-fluorouracil (FU) has been
found to be the most useful agent in the
clinic for the treatment of large-bowel
cancer, producing responses in -20% of
patients with measurable parameters of
disease activity (Carter and Friedman,
1974). It has previously been shown that
in only 1 of these 6 established human
colorectal xenograft lines, namely
HxELC2, was growth-inhibited by FU
treatment. It was interesting therefore
to examine any difference between this
tumour line and 3 other non-responders
with reference to the drug uptake, distri-
bution and thymidylate-synthetase inhi-
bition.
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MATERIALS AND AMETHODS
Our procedure for immune-deprivation by
thymectomy, lethal irradiation and syngeneic
marrowA transplantation has been reported
(Houghton et al., 1977). In these studies, 4
tumour pieces wi-ere implanted s.c. into the
flanks of each animal, in such a way that 4
discrete tumours evolved.
Tumour lines.-The histological, biochemi-
cal and growth-kinetic characteristics ofthese
xenograft lines have been reported (Houghton
and Taylor, 1978a, b). Briefly they constitute
the followNing listed in order of decreasing
differentiation.
HxBR Moderately well differentiated ade-
nocarcinoma ofthe rectum main-
tained in male mice (Passages 5
and 6)
HxAC4 Moderately w, ell differentiated ade-
nocarcinoma of the caecum
maintained in male mice (Pas-
sages 5 and 6)
HxHC, Moderately well differentiated ade-
nocarcinoma of the ascending
colon maintained in femnale mnice
(Passages 7, 8, 11, 12, 13)
HxGC3 Poorly differentiated adenocarci-
noma of the transverse colon,
maintained in male mice (Pas-
sages 4, 5, 8, 9, 10)
HxVRC5 Poorly differentiated adenocarci-
noma of the caecum maintained
in male mice (Passages 3, 4, 5,
7, 8)
HxELC2 Poorly differentiated carcinoma of
the caecum maintained in male
mice (Passages 3, 4, 5, 8, 9)
For clarity, the Hx prefix is dropped from
subsequent references in the text.
Measurement of tumour response. It has
been shown that xenografts growing in
immune-deprived mice have a wide distribu-
tion of growAth rates within any one passage
for a given tumour line (Pickard, Cobb and
Steel, 1975; Houghton and Taylor, 1978b).
The tumour growth-rate is at least partially
dictated by the host, and may reflect hetero-
geneity in the immune capabilities ofimmune-
deprived mice. Due to this variation oftumour
growAth-rates writhin a passage, it is often
difficult to show significant growth inhibition
after treatment wTith low dose levels of
effective agents, or those showing only slight
cytotoxic activity. Tumour growth-delay
is a relatively insensitive indicator of anti-
tumour activity in the xenograft system. In
this study, tumour response to chemotherapy
has been evaluated by growth-inhibition
measurement and by measuring the time
after treatment for 3H-TdR incorporation into
DNA to recover to the pretreatment level
(thymidine fractional incorporation, r'rFI1).
Details of TFI measurement and its relation-
ship to tumour growth-delay after treatment
have been reported (Houghton and Taylor,
1977; Houghton et al., 1977). Briefly, the TFI
recovery time is determined by measuring the
TFI (i.e., the proportion of total tumour 3H
that is incorporated into DNA 1 h after
administration of 3H-TdR) in groups of
tumours at various times after administra-
tion of the cytotoxic agent. Thus, a TFI
depression-recovery curve can be constructed
for a given treatment in a tumour line. The
time taken for t,he TFI to recover to the pre-
treatment level has been shown to be similar
to the mean tumour growth-inhibition in-
duced in groups of tumour-bearing hosts by
the same treatment. The TFI assay appears
to be more sensitive than measurement of
growth delay in detecting agents with slight
cytotoxic activity. In this paper the minimnum
TFI recovery time indicative of cytotoxicity
is 100 h. At this time after treatment the TFI
depression has usually passed its nadir, and a
relationship exists between the level of
depression and the TFI recovery time within a
tumour line. It also excludes agents which
cause a transient depression of 3H-TdR
incorporation into DNA, possibly due to
perturbation of endogenous nucleoside pools.
For the growth-delay studies, tumours were
treated at 8 mum diametei, and growth
delay assessed as the increase in time taken
for groups oftreated tumours to reach 4 times
their treatInent volume, compared to un-
treated tumours. At least 4 animals (16
tumours) were used to assess the effect ofeach
drug-dose level, in growrth-inhibition studies.
Radiolabelled FU studies.-5-Fluoro-6-3H-
uracil (3H-FU, Radiochemical Centre, Amers-
ham, sp. act. 1 mCi/mmol) was diluted with
non-radiolabelled FU (Roche) and each animal
received 100 mg/kg by i.p. injection, equiva-
lent to I [J&i/g body weight.
Tissue-extraction procedure. Animals were
killed at various times after drug administra-
tion and tissues removed and stored at -26°C.
Weighed tissues were submitted to a modified
Schmidt-Thannhauser extraction (Houghton
and Tavlor, 1977). In these studies the acid-
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soluble RNA and DNA fractions were each
collected in a total volume of20 ml. After the
collection of each fraction, the pellet was
washed twice in ice-cold 0-2 M perchloric acid.
The second of these washings was retained
and the radioactivity measured. This served
as a measure of the cross-contamination
between fractions. The level of radioactivity
in these fractions was used as the background
count for the subsequent fraction. Following
extraction ofDNA the pellet was resuspended
in 03 M NaOH at 37°C (20 ml).
RNA was assayed using the orcinol reaction
(Ashwell, 1957), DNA using diphenylamine
(Burton, 1956) and protein by the method of
Lowry et al. (1951).
3H-Deoxyuridine incorporation (3H-UdR).-
Measurement of 3H-UdR incorporation into
human tumour and mousenormal-tissue DNA
was made 24 h after administration of FU
(non-radiolabelled). One hour before being
killed animals received 25 ,Ci 3H-UdR
(deoxy-6-3H-uridine, 10 Ci/mmol, Radio-
chemical Centre, Amersham). Tissues were
stored at -26°C, until submitted to the
modified Schmidt-Thannhauser extraction.
Results are expressed as the percentage
inhibition of3H-UdR fractional incorporation
into DNA, compared to that measured in
untreated tumours of the same line and of
equal weight.
Radioactivity was measured by liquid
scintillation spectrometry (Intertechnique
Ltd. SL 40) using a scintillation emulsion of
toluene containing0 6%w/vbutylPBD 7parts
and Triton X100 3 parts. Corrections were
made for counting efficiency and quenching.
Protein fractions were dark-adapted for 24 h
before counting toreduce chemoluminescence.
All chemotherapeutic agents used in this
study were prepared immediately before i.p.
injection, in either sterile water or normal
saline, except for methyl CCNU and penta-
methylmelamine, which were dissolved in
DMSO (10% v/v of final volume) and sus-
pended in 5% v/v Tween 80. Animals were
injected at about the same time of day, each
receiving a single dose of the selected cyto-
toxic agent.
RESULTS
The time taken for TFI to recover to the
pretreatment level has been recorded for
up to 7 agents for each tumour line (Table
I). A zero value has been recorded when
there was no significant depression in
TFI and no growth delay after treatment.
The maximum dose level used was lethal
to -5% of animals treated (LD5), but
even at this level most agents produced
little inhibition of tumour growth. In
only one experiment was no TFI recovery
observed, the TFI continuing to decrease
with time after treatment. This occurred
in tumour line AC4 after methyl CCNU*,
and was associated with a marked reduc-
tion in tumour volume (>90%) within
20 days. This is the only example in this
report that would be regarded as an
objective response if the clinical criterion
of a 50% reduction in the product of the
tumour diameters were the basis for
evaluation. In other cases (e.g. tumour
lines ELC2 and VRC5 after cyclophospha-
* Urea, 1-(2-chloroethyl)-3-(4 methyl cyclohexyl)-
1-nitroso.
TABLE I.-Mean 3H-TdRFractional Incorporation (TFI) Recovery Times (h)forXenograft
Tumours after Treatment with Various Dose Levels of Cytotoxic Agents. The Highest
Dose Level of Each Agent is -LD5 of Tumour-bearing Animals
Agent (mg/kg)
, . .A
Hx CY
tumour ,
line 50 100 200
BR ND ND 240
AC4 ND 60 100
HC1 0 50 80
GC3 ND 50 110
VRC5 20 60 600
ELC2 100 340 700
FU Methyl CCNU
50 100 200 17-5 35
ND 75 95 120 ND
ND 0 0 >350* >350*
ND 0 0 90 120
0 0 60 70 150
0 0 0 70 550
80 500 900 70 150
Act. D cis-DDP
0 075 0-15 03 3 6
ND ND
0 0 0 ND
0 0 0 0 45
ND ND 70 0 30
ND 50 120
30 40 80 96
PMM DOX
50 100 10 15
ND 95 ND
ND 80 140
0 0 0 100
70 110 80 >200
ND 96 > 150
90 150 ND ND
ND=not determined.
* TFI could not be determined beyond this time due to tumour-volume regression.
t CY=Cyclophosphamide; FU=5-Fluorouracil; Act D=Actinomycin D; cis-DDP ci8-dichloro; PMM-
pentamethylmelamine, CB1O-370; DOX=Doxorubicin.
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mide (CY) or ELC2 after FU), there was
considerable growth inhibition (and similar
TFI recovery time) but little or no tumour-
volume reduction (<10%). Tumour-vol-
ume reduction appears to be a poor indica-
tor of cell kill in these xenografts. We have
therefore used growth delay or TFI
recovery time as the criteria for assessing
tumour response to therapy.
In order to compare the "response rate"
in this series of xenografts with that
observed clinically, a positive response
has been defined as a growth delay >2
tumour-volume doubling times (calcu-
lated in untreated tumours at the same
passage) after treatment. Tumour res-
ponses to each agent, given at the LD5
dose level, are shown in Table II. Using
this criterion, only 5 positive responses
TABLE II. The Response of Tumours to
Chemotherapy. A Positive Response is
Defined aS a Growth Inhibition > 2
Volume Doubling Times for Untreated
Tumours of the Same Line and Volume
on that Passage. Agent given at LD5
level
Hx ,-
Tumour Me
line CY FU CC
BR - - I
AC4 - -
HC1 - -
GC3 - -
VRC5 -
ELC2 + +
ND not dletermined.
Agent
ethyl Act
>NU D
ND ND
Cis-
DDP
ND
ND
+ ND
PiMM DOX
ND ND
ND _
ND -
ND
were obtained from the 32 tumour-drug
combinations that were examined (16%).
If a less stringent criterion were used (i.e.,
> 1 tumour-volume doubling time) the
response rate at the same level at host
toxicity would be 8/32 (25%). Only CY,
FU and methyl CCNU induced positive
responses. (Table II).
Studies with FU: effect on 3H-UdR
incorporation
The data in Table III show the
dose of FU causing a 5000 inhibition of
3H-UdR fractional incorporation (ID50)
TABLE III.-The Dose Level ofFU giving a
5000 Inhibition of 3H-UdR Incorpora-
tion into DNA. Meacsurements were
made 24 h after Drug Administration, at
which time Inhibition was Maximal.
'Normal Tissues were Taken from Xeno-
graft-bearing Animals
Tissue
BR
AC4
HCG
GC3
VRC5
ELC2
Mouse marrow
Mouse small intestine
ID50
(mg/kg)
18
24
13
27
36
22
22
22
24 h after drug administration. At this
time after treatment there is a dose-related
inhibition of 3H-UdR incorporation into
DNA in each tumour line. The ID50 for
normal mouse marrow and small intestine
are also shown. In each case 3H-UdR
incorporation is inhibited, which suggests
that each of the tumour lines studied is
able to activate FU. The ID50 dose levels
of FU in the non-responding tumours lie
either side of that in tumour line ELC2,
which responds to FU. Consequently, it is
not possible to draw conclusions concern-
ing the inhibition of 3H-UdR incorpora-
tion into DNA and tumour-growth inhibi-
tion. Even at the highest dose level of FU
(200 mg/kg, LD5) the only tumour line
to show a significant growth inhibition
was ELC2 (Table II).
Distribution and incorporation of 3H-5FU
The total radioactivity in individual
tumours of each of 4 tumour lines (d/min/
mg wet weight) was measuied at various
times for up to 48 h after a single adminis-
tration of 3H-5FU (total dose 100 mg/kg).
The results are presented in Table IV.
There appears to be little difference
between the gross uptake of 3H-5FU into
each tumour line. In addition, the 5FU
sensitivity in HxELC2 tumours cannot be
explained by a selective retention of this
agent. One problem in understanding the
meaning of drug-uptake studies in solid
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TABLE IV. The Gro88 Uptake of 3H-FU
at Various Times after Administration
(ct/min/mg tumour wet wt±s.e. mean)
Hx I
Tumour -
line 1
HC1 552 - 67
GC3 556- 20
VRC5 474-4-20
ELC2 4354 16
Fime after administration (h)
A
4
630 ± 168
442-1- 12
333 ± 4
8 24 48
395 16 - -
364±8 282f 8 258+412
290-4- 8
337-1 12 223 4 1572z-8
tumours is that often a, large proportion
of necrosis is present within the tumour,
and that the proportion oftumour which is
necrotic increases with tumour size. Con-
sequently, where drug uptake into viable
areas of tumour is greater than that into
necrotic zones because ofa more functional
vasculature, the overall drug uptake in a
tumour may be determined by the ratio of
viable to necrotic tissue therein. In this
study, there was no significant difference
between the mean weights of tumours
between tumour lines or at the various
intervals used. All tumours used weighed
less than 600 mg, and within the weight
range used there wa,s no relationship
between the gross uptake of 3H-FU and
tumour weight in any line.
The proportional distribution of 3H-FU
is shown in Table V. The non-incorporated
fraction contains radioactivity which pre-
sumably includes both extracellular and
intracellular material. In each tumour line
the greatest proportion of radioactivity is
in the non-incorporated fraction for up to
48 h in the tumours studied, and little has
been measured in the DNA or protein
fractions. The proportion of radioactivity
bound to RNA is highest in tumour line
HC1 but is similar in the other tumour
lines. RNA specific activity (ct/min/mg
RNA) at various times after treatment is
shown in Table VI. At intervals for up to
8 h after 3H-FU administration the speci-
fic activity in ELC2 tumours is lower than
within the other 3. Between 1 and 2 days
after treatment the RNA specific activity
decreased in ELC2, whereas no significant
change was measured in tumour line GC3.
In both tumour lines there was a decrease
TABLE V.-The Distribution of Radioactivity in Xenografts at Various Times
after Administration of 3H-FU (means±s.e.)
Distribution of radioactivity (0% total)
Time (h)
4
8
1
4
8
24
48
1
8
1
4
8
24
48
non-incorporated
90-5
83 7
82-2
94 6
92-2
89-3
88- 1
86 7
93 1
87-2
93.7
91-5
90-9
86-4
9.3 3
RXA
9 -0--0-5
13-9-0- 7
16 5±0 4
5-1±0 4
7 -44-0 4
10-2±0-3
11-1±0-4
12-6±1-9
6-5±0-4
11 5 L0 4
5-7±09
7-7±0-5
8-4±0-9
12-8±1-0
6-4±2-2
DNA
0 2 0-1
1-7±0-4
0-440- 3
<0*1
<0-1
<0-1
<0-1
<0-1
0-2 0-1
<0-1
0-440-1
0-4±01
0-4±0-1
0-4±0-0
<0-1
Protein
0 6±0 1
0 7±0 2
0 9±0 2
0 3+0-1
0 4±0-1
0 4±0-1
0 8±0-2
0 7±0 3
0 2±0 1
1 24-0 4
0 2±0-01
0-4±0-1
0-3±0-1
0-4±0-1
0-2±0 0-03
TABLE VI. R1NA Specific Activity (10-3x ct/min/mg RNA) at Various Times
after 3H-FU Admiinistration in Human Xenografts (means+s.e.)
Hx
Tumouir
line I
HC1 7-81 -2
GC3 4-3±0-4
VRC5 4-5±-0- 8
ELC2 3-0 0-4
Time after 3H-FU administration (h)
4
12 -1±2-4
5-2±0-4
:3 6 0-8
11 -1±0-8
6-540-4
6-4 0-4
2-940-4
24
5-90-4
Hx Tumour
line
EtC1
GC3
VRC5
ELC2
48
5-8±0-4
2 5± 0 ) 4 1-1±0 -04
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in assayable RNA at 48 h compared with
the RNA/mg I h after FU. This decrease in
RNA/mg in ELC2 (17.80o) was not suffi-
cient to account for the decrease in RNA
specific activity observed, unless aberrant
RNA, into which FU had been incorpora-
ted, was selectively degraded. A decrease
of 22% in the assayable RNA/mg in GC3
tumours at 48 h was not associated with a
fall in the RNA specific activity.
I)1SCUSSION
The data presented show that in this
series of human colorectal tumour xeno-
grafts each is unique in its sensitivity to
the spectrum of chemotherapeutic agents
used. There appeared to be no similar
pattern of chetnosensitivity between
tumour lines. Two of the 6 lines (VRC5
and ELC2) responded to CY, using the
criterion for a positive response given for
Table II. Similarly, 2 tumour lines respon-
ded to methyl CCNU (AC4 and VRC5).
Only ELC2 tumours responded to FU, and
this tumour line was sensitive to CY but
not to methyl CCNU. Examination of the
data in Table I shows that 3 agents demon-
strated at least marginal activity against
a high proportion of the tumour lines
( 00 h TFI recovery time) at the LDs
dose level: CY showed activity against
5/6 lines and both methyl CCNU and
doxorubicin were active against all the
tumour lines in which they were tested.
Currently, there are no assay systems
which allow determination of the chemo-
sensitivity of an individual patient's
tumour before chemotherapy. Until such
"patient assays" are feasible, combinations
of those agents which individuallv have
shown activity against the disease are
most likely to produce the greatest effect
on the colorectal tumour population
(Nathanson et al., 1969). It has been the
object of most combination drug pro-
grammes to increase the percentage of
patients with positive responses totherapv,
but median survival cannot be expected to
improve until more than half the patients
show such responses (De Vita and Schein,
1973). Clinically, the incidence of complete
tumour regression is very low, and the
majority of tumours fail to exhibit even
partial responses in this disease. From
the data presented, the combination ofCY
doxorubicin and methyl CCNU would
appear promising as this would induce
responses in the greatest proportion of
tumours in the current xenograft series.
Whether this combination, administered
either simultaneously (with a proportion-
ate reduction in the dose level of each
component) or sequentially (where the
schedule is determined according to the
requirements of normal tissues), would
achieve as great an effect on individual
tumours as the nmost effective single agent
(given at an equivalent level of toxicity)
remains to be determined. This 3-agent
combination may have advantages in that
individual drugtoxicities, in particular car-
diotoxicity and prolonged marrow depres
sion for doxorubicin and methyl CCNU
respectively, could be reduced. Evalua-
tion of this combination in xenografts will
be undertaken in the near future.
Complete tumour regression in the
xenograft system must be regarded with
some caution, since it is possible that host
residual immunity may be able to eradi-
cate small numbers of viable tumour cells
after effective chemotherapy (Kopper and
Steel, 1975). In these experiments, all the
AC4 tumours exhibited a similar volume
reduction after methyl CCNU treatment,
in contrast to the variation in response to
chemotherapy within an oat-cell xenograft
line reported by Kopper and Steel.
In this series of xenografts, only one
line responded to FU. However, this fact
alone is a poor criterion for suggesting
that these tumours are representative of
the "human disease" as a whole. With such
a small number of tumour lines it is
unlikely that a truly representative sample
would have been selected at surgery. Of
importance is that the xenograft data is in
agreement with clinical evaluation, that
tumour responses are unpredictable, and
chemotherapy, at this time, is not very
effective against colorectal carcinoma. CY,
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methyl C)CNU and FU each exhibit signi-
ficant activity against individual tumour
lines (Table II) whereas actinomycin-D,
cis-DDP and doxorubicin do not. This is
in agreement with the general clinical
ranking of these agents (Carter and Fried-
man, 1974; Kovach et al., 1973).
One of the possible reasons for the poor
response amongst patients with colorectal
carcinoma after FU therapy is that the
tumours lack the enzyme systems capable
of converting FU to the active FdUMP
(see Reyes, 1969; Kent and Heidelberger,
1972). It is apparent that each tumour
line presented here possesses this ability.
Whether it would be possible to achieve
drug levels in the patient capable of
inhibiting thymidylic-acid synthesis to
the same degree as that observed in the
xenografts is open to speculation. It is
apparent that even when 3H-UdR utiliza-
tion is reduced by >900o from the control
level, a tumour response in terms ofgrowth
delay is not necessarily observed.
The difference in response between
ELC2 and the other 3 xenograft lines can-
not be explained by a differential uptake,
distribution or elimination of FU. Simi-
larly, the incorporation of 3H-FU into
RNA was lower in ELC2 than in the other
tumour lines.
There are several mechanisms that may
explain the apparent lack of tumour res-
ponse after inhibition of thymidylic acid
synthesis by FU. The lesion may not
prove lethal to the cell owing to the capa-
city to use "salvage" pathways (Sneider
and Potter, 1969) (i.e., the use ofpreformed
thymidine). (Madoc-Jones and Bruce
(1968) have demonstrated the reversal of
FU toxicity by TdR in vitro.) Alterna-
tively, cells may be able to survive for a
considerable period before the inhibition
of thymidylate synthesis becomes a lethal
lesion. At 24 h after FU administration
there is maximum inhibition of 3H-UdR
incorporation into DNA, but inhibition
may be reversed before the lesion becomes
lethal. Myers, Young and Chabner (1975)
have suggested that disinhibition of thy-
midylate synthetase may occur through
the accumulation of dUMP, although 24 h
after FU no increase in dUMP pools was
measured in malignant or normal mouse
tisstues by these workers. Initial studies
(Houghton, Houghton and Taylor, 1978)
have shown that there is a prolonged
increase in 3H-TdR uptake and utiliza-
tion after FU administration in 3 FU
insensitive tumour lines, but is decreased
significantly in ELC2 tumours. This may
be due to pool-size perturbation, a genuine
compensation for the inhibition of TMP
production from dUMP, or possibly a cell-
synchronizing effect of the treatment
(Camplejohn, Schultze and Maurer, 1977).
It is anticipated that expansion of the
current 6 colorectal xenograft lines will
simulate a human tumour population, and
that such a population will provide a more
realistic screen for the selection of new
agents, and in selecting drug combinations
which will have significant activity clini-
cally against a high proportion of colo-
rectal tumours. Becauise tumour response
to treatment is more readily defined in a
xenograft system than in the patient, it
mav be possible to relate biochemical and
biological parameters of the tumours to
their chemosensitivity, eventually allow-
ing for prediction of tumour sensitivity of
individual patients, on the basis of corre-
lations made in xenografts.
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